Hims & Hers Faces Critical Test Amid Regulatory and Legal Turmoil

Hims & Hers US4330001060

The upcoming quarterly report from telemedicine provider Hims & Hers Health, scheduled for release on February 23, arrives at a pivotal moment for the company. Its share price has been cut nearly in half since the start of the year, a dramatic decline fueled by a regulatory crackdown and a high-stakes patent lawsuit.

Investor sentiment has soured dramatically in recent weeks. After trading at $31.32 on January 14, the stock plummeted to approximately $16.30 by mid-February. This sell-off has occurred against a backdrop of increasing short interest, which reached a record 65% of available shares in January, according to Hazeltree data. LSEG figures further indicate that short interest hit an all-time high on February 12. The stock's 52-week range now stands between $15.63 and $72.98.

Regulatory and Legal Headwinds Intensify

The core of the recent crisis stems from actions targeting the company's foray into weight-loss medications. On February 7, the U.S. Food and Drug Administration (FDA) announced it would take "decisive steps" against firms marketing compounded versions of GLP-1 drugs. This was followed just two days later by a patent infringement lawsuit from pharmaceutical giant Novo Nordisk.

In response, Hims & Hers was compelled to withdraw its recently launched, lower-cost alternative to Wegovy, priced at $49. The company issued a sharp rebuttal, characterizing the lawsuit as "a brazen attack by a Danish corporation on millions of Americans who rely on personalized medicine."

Strong Operational Performance Presents a Contrast

Despite the market and legal drama, the company's most recent operational results tell a more robust story. For the third quarter of 2025, Hims & Hers reported:
* Revenue of $599 million, representing year-over-year growth of 49%.
* A subscriber base of 2.5 million, a 21% increase from the prior year.
* Operating cash flow of $148.7 million.

Furthermore, the company's board has authorized a share repurchase program worth $250 million.

Divergent Views from Wall Street Analysts

Market experts are divided on the stock's outlook. Among the 15 analysts covering the company, ten currently recommend a Hold rating, three advocate for a Buy, and two advise Selling. The average price target sits at $29.96, nearly double the current trading price, reflecting the stark divide in expectations.

Recent adjustments highlight the uncertainty. Citigroup reaffirmed its Sell recommendation on February 9 while lowering its price target to $16.50. Conversely, BTIG Research maintained its Buy rating but significantly reduced its target from $85 to $60.

All Eyes on the February 23 Earnings Call

The management's conference call, scheduled for 11:00 PM Central European Time on February 23, is now under intense scrutiny. Investors will be listening closely for the leadership's strategy to navigate the newly erected regulatory and legal barriers. Prior company guidance targeting over $6.5 billion in revenue by 2030 is now being critically re-evaluated following these significant setbacks in its GLP-1 initiative.